Latest Antisense RNA Stories
- Isis Outperforms 2014 Projections for Pro Forma Net Operating Loss and Year-end Cash CARLSBAD, Calif., Feb. 27, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
SAN DIEGO, Dec.
SAN DIEGO, Feb.
- Arcturus proprietary LUNAR(TM) delivery technology demonstrates exceptional potency in vivo, ED(50) of 0.020 mg/kg SAN DIEGO, Jan.